Summary & Overview
HCPCS J0561: Injection, Penicillin G Benzathine, 100,000 Units
HCPCS Level II code J0561 denotes an intramuscular injection of penicillin G benzathine, 100,000 units. This medication is a long-acting formulation of penicillin used for treatment or prophylaxis of susceptible bacterial infections and is relevant across outpatient and ambulatory care settings. Clarity in coding and billing for this drug matters nationally because it affects access to essential antibiotic therapy, influences payer coverage decisions, and informs utilization and cost monitoring for injectable medications.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J0561, typical sites of service where the injection is administered, common modifiers used in billing practice, and a synopsis of what information is available versus not provided. The publication presents benchmarks and coverage perspectives where available, notes implications for coding accuracy, and outlines areas where policy updates or payer-specific guidance commonly affect claim adjudication.
This summary is written for a national audience and is intended to help billing professionals, clinicians, and policy analysts understand the role of J0561 in routine outpatient antibiotic administration and in payer coverage frameworks. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code J0561 describes an injection of penicillin G benzathine, 100,000 units. The service is a parenteral antibiotic administration intended for intramuscular injection to treat or prevent susceptible bacterial infections. Typical site of service is an ambulatory clinic, physician office, urgent care, or other outpatient setting where intramuscular injections are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant woman presents to the outpatient obstetrics clinic at 28 weeks' gestation for routine prenatal care. She reports a history of a positive screening test for syphilis in a prior clinic visit. The clinician confirms a diagnosis of early latent syphilis and schedules an intramuscular injection of penicillin G benzathine. The medication is supplied as J0561 per 100,000 units; dosing for syphilis is typically given as benzathine penicillin G 2.4 million units intramuscularly (which is administered as multiple syringe/ampule draws depending on packaging). The clinical workflow includes verification of allergy status (no penicillin allergy), informed consent, medication preparation under aseptic technique, administration in the gluteal muscle, observation for 15–30 minutes for adverse reaction, documentation of lot number and amount administered, and scheduling follow-up serologic testing. Typical sites of service are outpatient clinic, physician office, or public health clinic. Common patient scenarios for J0561 include treatment of syphilis, prophylactic use in certain bacterial infections per guideline-directed care, and intramuscular therapy provided in ambulatory settings for patients without penicillin allergy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard) |